Published Date : 18 Aug 2023
The global critical limb ischemia treatment market size surpassed USD 4.43 billion in 2022 and it is expected to rake around USD 9.18 billion by 2032, poised to grow at a CAGR of 7.56% during the forecast period 2023 to 2032.
Critical limb ischemia (CLI) is a crucial form of peripheral arterial disease (PAD) in which the blood supply to the extremities (feet, legs, and hands) is diminished due to chronic inflammation brought on by atherosclerosis (thickening of arteries walls that is progressive), resulting in excruciating discomfort and sores or ulcers. Age (those 60 and older are at greater risk of developing this sick condition), obesity, diabetes, high cholesterol, sedentary lifestyle, smoking, and high blood pressure are the main risk factors for critical limb ischemia. Symptoms of critical limb ischemia include ischemic rest discomfort, gangrene, and tissue loss.
The demand for medicines is predicted to rise as the incidence of critical limb ischemia rises, propelling the worldwide market for chronic limb ischemia treatment. Furthermore, the global market for chronic limb ischemia treatments is projected to be driven by growth in healthcare spending and an increase in clinical trials. The expansion of the pharmaceutical sector, advancements in healthcare infrastructure, an increase in the number of clinical trials, and an increase in the population of patients with critical limb ischemia are all anticipated to play a significant role in driving the global market.
Based on treatment, the devices segment is anticipated to hold a significant share of the worldwide critical limb ischemia therapy market. Stents and dilation devices successfully dilate the artery while safeguarding the arterial wall. Patients experience a higher quality of life thanks to these devices' low complication rates and technical success. Another reason for the segment's dominance is the rise in FDA approvals and patient preference for revascularization as the initial course of treatment.
The peripheral dilatation system is expected to make up a sizable portion of the devices segment during the forecast period. Leading companies in the critical limb ischemia market are concentrating on creating and introducing cutting-edge peripherals. The Peripheral System by Radianz Radial will be used by people, according to a June 2022 announcement.
North America is anticipated to lead the global market for critical limb ischemia treatments based on region. The region's market is expected to grow due to the area's large population, unmet medical requirements, and rising patient awareness. From 2023 to 2032, the market in Asia Pacific is projected to expand at a rapid CAGR.
Critical Limb Ischemia Treatment Market Report Scope:
|Market Revenue in 2023
|USD 4.76 Billion
|Projected Forecast Revenue in 2032
|USD 9.18 Billion
|Growth Rate from 2023 to 2032
|CAGR of 7.56%
|2023 To 2032
|North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
In the upcoming years, North America will likely lead the global market for critical limb ischemia treatments. During the forecast period, the market in the area is anticipated to expand at a moderate CAGR. The growth can be attributed to the rise in government activities and awareness about CLI and other risk-associated conditions, as well as to increases in healthcare spending, disposable income, and the accessibility to cutting-edge technology in the area. A new study estimates 2 million and 3 million Americans have significant limb ischemia.
Within 2022 and 2032, the market in the Asia Pacific is projected to expand at a rapid CAGR. The growth in the prevalence of CLI in nations like China and India, the expansion in the senior population, and the explosion in government initiatives and healthcare spending are driving the market for critical limb ischemia treatment in the area. The region's market is expected to grow due to the area's large population, unmet medical requirements, and rising patient awareness. Because of the rise in disposable income brought on by economic growth in emerging economies like China and India, consumers' purchasing power is improving. In the foreseeable future, this is anticipated to increase the market in these nations.
Market Drivers and Opportunities:
Increased demand for peripheral dilatation systems will open up a wide range of profitable markets
According to the TMR study, peripheral dilation systems are frequently employed to lower CLI-related morbidity and mortality. The market for treating critical limb ischemia has seen increased demand for various dilating devices due to the preference for revascularization as the first-line treatment. Technologically enhanced peripheral dilatation devices will become more widely used shortly, opening up new opportunities.
Antiplatelet drug preference by patients to promote growth prospects
Increased desire for minimally invasive procedures has boosted the potential of antiplatelet medications. Expanding product lines by pharmaceutical businesses will drive significant revenues in the pharmaceutical market. During the projected period, the widespread accessibility of these drugs will determine revenue streams in the antiplatelet drugs sub-segment. Pharmaceutical companies will be able to expand their product pipeline in the market for treating critical limb ischemia due to an increase in the number of antiplatelet clinical trials.
The alarming health and financial impact of critical limb ischemia (CLI) driving the market
A significant factor driving the critical limb ischemia therapy market is the alarming health and financial impact of critical limb ischemia (CLI), particularly in developing nations. The commercial prospects are strengthened by methods that enable minimally invasive arterial revascularization procedures.
Advances in gene and cell therapies will open up new opportunities
For companies in the critical limb ischemia therapy market, advances in gene and cell therapies will open up new opportunities, particularly for addressing the needs of patients with high surgical risk, comorbidities, and situations where revascularization is not an option. Thus, as the number of patients who cannot be revascularized rises, so will the window of opportunity for businesses operating in the critical limb ischemia therapy industry.
Major Key Players:
Buy this Research Report@ https://www.precedenceresearch.com/checkout/2498
You can place an order or ask any questions, please feel free to contact at email@example.com | +1 9197 992 333